Noninvasive prenatal diagnosis for pregnancies at risk for β-thalassaemia: a retrospective study
- 1 January 2021
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 128 (2), 448-457
- https://doi.org/10.1111/1471-0528.16295
Abstract
Objective To evaluate the clinical feasibility of noninvasive prenatal diagnosis (NIPD) for beta-thalassaemia using circulating single molecule amplification and re-sequencing technology (cSMART). Design Through carrier screening, 102 pregnant Chinese couples carrying pathogenic HBB gene variants were recruited to the study. Pregnancies were managed using traditional invasive prenatal diagnosis (IPD). Retrospectively, we evaluated the archived pregnancy plasma DNA by NIPD to evaluate the performance of our cSMART assay for fetal genotyping. Setting Chinese prenatal diagnostic centres specialising in thalassaemia testing. Population Chinese carrier couples at high genetic risk for beta-thalassaemia. Methods Fetal cell sampling was performed by amniocentesis and HBB genotypes were determined by reverse dot blot. NIPD was performed by a newly designed HBB cSMART assay and fetal genotypes were called by measuring the allelic ratios in the maternal cell-free DNA. Main outcome measures Concordance of HBB fetal genotyping between IPD and NIPD and the sensitivity and specificity of NIPD. Results Invasive prenatal diagnosis identified 29 affected homozygotes or compound heterozygotes, 54 heterozygotes and 19 normal homozygotes. Compared with IPD results, 99 of 102 fetuses (97%) were correctly genotyped by our NIPD assay. Two of three discordant samples were false positives and the other sample involved an incorrect call of a heterozygote carrier as a homozygote normal. Overall, the sensitivity and specificity of our NIPD assay was 100% (95% CI 88.06-100.00%) and 97.26% (95% CI 90.45-99.67%), respectively. Conclusions This study demonstrates that our cSMART-based NIPD assay for beta-thalassaemia has potential clinical utility as an alternative to IPD for pregnant HBB carrier couples.Keywords
Funding Information
- National Natural Science Foundation of China (81501268, 81771599)
This publication has 41 references indexed in Scilit:
- Molecular epidemiological survey of haemoglobinopathies in the Guangxi Zhuang Autonomous Region of southern ChinaClinical Genetics, 2010
- Beta-thalassemiaOrphanet Journal of Rare Diseases, 2010
- Beta-thalassemiaGenetics in Medicine, 2010
- Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasmaProceedings of the National Academy of Sciences of the United States of America, 2008
- Prenatal Diagnosis of β-Thalassemia by Reverse Dot-Blot Hybridization in Southern ChinaHemoglobin, 2006
- Carrier screening for ?- and ?-thalassemia in pregnancy: the results of an 11-year prospective program in Guangzhou Maternal and Neonatal hospitalPrenatal Diagnosis, 2005
- The prevalence and spectrum of and thalassaemia in Guangdong Province: implications for the future health burden and population screeningJournal of Clinical Pathology, 2004
- HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene serverHuman Mutation, 2002
- Antenatal screening and fetal diagnosis of β-thalassemia in a Chinese population: prevalence of the β-thalassemia trait in the Guangzhou area of ChinaHuman Genetics, 1996
- Reverse dot blot probes for the screening of β-thalassernia mutationsin Asians and American blacksHuman Mutation, 1994